What's Actually Happening to Your Hormones in Your 40s and 50s

Why Midlife Hormones Deserve a System-Level View

The female endocrine system in midlife is usually described as "menopause," but that word only names the final event — the cessation of menses for twelve consecutive months. The biologically interesting period is the decade before that milestone, when the ovaries, adrenals, pituitary, and liver-derived binding proteins all shift in interacting ways.

Most public conversations about midlife hormones are organized around symptoms: hot flashes, sleep disturbance, mood changes, libido changes, joint aches. That symptom-level framing is useful for patient recognition, but it hides the biology underneath — and the biology is what determines whether any given treatment has a real shot at working.

This article is the opposite of a symptom-to-protocol funnel. It's a research-anchored overview of which hormones change, how they change, and what the major endocrine bodies — the Endocrine Society, ISSWSH, and NAMS — have said about that biology in their published guidelines. What any individual patient should do about any of this is a clinical conversation with a prescribing physician, not something any article can answer.

The Ovarian Transition: Estradiol and Follicular Depletion

The central event of midlife is the depletion of the ovarian follicular reserve. Women are born with a finite number of follicles (on the order of 1-2 million at birth, declining to roughly 300,000-400,000 at puberty) and this pool depletes progressively over the reproductive lifespan. The rate of depletion accelerates sharply in the late 30s and early 40s.

Because estradiol is primarily secreted by the granulosa cells of developing follicles, fewer available follicles means less estradiol production. But the transition is not a smooth decline. The STRAW+10 staging system published by the Stages of Reproductive Aging Workshop describes perimenopause as a period of erratic hormonal fluctuation, with cycles that can feature transiently higher estradiol peaks alongside longer stretches of low estradiol.^[1] This oscillation is one reason the symptom picture in perimenopause is often described as more unpredictable than postmenopause — the system is destabilizing, not simply running down.

FSH rises as the pituitary tries to stimulate remaining follicles. Elevated FSH (typically measured above 25-30 mIU/mL in the late perimenopausal stage) is one of the more reliable biochemical markers of the transition, though the Endocrine Society and NAMS both note that a single FSH blood draw doesn't tell you much on its own — the number swings a lot from cycle to cycle.

Progesterone: The First Hormone to Fall

Progesterone is produced primarily by the corpus luteum after ovulation. When ovulation occurs reliably in every cycle, progesterone rises predictably in the luteal phase. When ovulation becomes less reliable — a hallmark of early perimenopause — the amount of progesterone you make in the second half of your cycle drops.

For many women, the first detectable hormonal change of midlife is anovulatory or short-luteal-phase cycles in the late 30s and early 40s, so progesterone falls while estrogen is still mostly intact. This is the biological basis for what's sometimes called "estrogen dominance" in the perimenopausal years — not that estrogen is elevated in absolute terms, but that the estrogen-to-progesterone ratio shifts because progesterone falls first.

Progesterone's role extends beyond the reproductive system. It acts on GABA-A receptors via its metabolite allopregnanolone, which is part of why it's associated with sleep and mood effects. The Endocrine Society and NAMS both address progesterone in their menopause hormone therapy guidelines, though the published recommendations focus on endometrial protection in women taking estrogen rather than on symptom-directed progesterone use.

Androgens: Testosterone, DHEA, and the Adrenal Contribution

Testosterone in women is produced from two sources: the ovaries (roughly 25%) and the adrenal glands, which produce androgen precursors like DHEA and DHEA-S that are converted peripherally to testosterone (roughly 50%), with the remaining 25% from direct peripheral conversion.

Ovarian testosterone production does decline with menopause, though not as dramatically as ovarian estradiol production. Adrenal DHEA, by contrast, declines gradually and progressively across the adult lifespan — a phenomenon sometimes called "adrenopause," with DHEA-S at age 70 typically about 10-20% of its peak value in the 20s.

The ISSWSH Global Consensus Position Statement on the Use of Testosterone Therapy for Women (Davis SR et al., 2019) is the most frequently cited modern research document on female androgen physiology and testosterone as a clinical intervention.^[1] That statement, endorsed by ISSWSH, the International Menopause Society, the Endocrine Society, and multiple national menopause societies, summarizes the published evidence that:

- Testosterone levels in women decline with age and surgical menopause. - Testosterone therapy has research support for use in postmenopausal women with hypoactive sexual desire disorder (HSDD). - There is no FDA-approved female testosterone product in the US; female testosterone therapy in the US is prescribed off-label using compounded preparations or lower-dose adaptations of male-approved products.

Whether any particular woman is an appropriate candidate for such therapy is a clinical decision made by a prescribing physician based on history, symptoms, bloodwork, and risk factors. See our deeper explainer on the US prescribing landscape for female testosterone for the regulatory history.

SHBG: The Binding Protein That Changes the Signal

Sex hormone binding globulin (SHBG) is a liver-produced protein that binds circulating sex hormones — primarily testosterone and estradiol — and controls how much of each is biologically available. Only unbound ("free") hormone is biologically active. Total testosterone and free testosterone can diverge dramatically depending on SHBG.

Several factors raise SHBG, reducing free testosterone even when total testosterone looks normal on a lab panel:

- Estrogen therapy (oral estradiol in particular, due to first-pass liver exposure) - Oral combined hormonal contraception, which is well-documented to raise SHBG by a factor of 2-4 in many users^[1] - Hyperthyroidism - Hepatic disease

Several factors lower SHBG:

- Insulin resistance and metabolic syndrome - Hypothyroidism - Exogenous androgen use - Obesity (in some studies)

For a full discussion of the contraception-SHBG relationship and what the published clinical literature shows about its reversibility, see Hormonal Contraception and the Androgen Axis.

The Thyroid and Cortisol Axes Don't Sit Out the Transition

The sex hormones are the focus of most midlife discussions, but the broader endocrine system participates. Thyroid hormone and cortisol both interact with sex hormones in ways that are relevant to the clinical picture.

Thyroid. The prevalence of subclinical and overt hypothyroidism rises with age, and women are affected more than men. Thyroid hormone affects SHBG, binding protein synthesis, and tissue sensitivity to estradiol. Thyroid dysfunction can blunt the effect of any other hormone intervention, which is part of why comprehensive endocrine workups typically include TSH and, depending on clinical context, free T4 and antibodies.

Cortisol and the adrenal axis. Chronic stress, poor sleep, and circadian disruption all affect the hypothalamic-pituitary-adrenal axis. Elevated cortisol is associated with lower DHEA-S and with insulin resistance (which in turn lowers SHBG). The HPA axis and HPG axis (hypothalamic-pituitary-gonadal) are linked — interventions that affect one often affect the other indirectly.

The Endocrine Society's clinical practice guidelines on menopause and androgen therapy in women both emphasize that hormone labs need to be read in context, not as a row of isolated numbers — the interaction among axes is what determines the clinical picture.

What the Guidelines Actually Say

The major endocrine bodies have published position statements and clinical practice guidelines covering various aspects of midlife hormone biology. At a high level:

These guidelines do not all agree on every point. They differ on the role of testosterone for non-sexual indications, the preferred forms of estrogen and progesterone, the handling of compounded bioidentical hormones, and the criteria for initiating therapy. For a head-to-head summary see what the major guidelines actually say about women's hormones.

What all the guidelines consistently recommend is that midlife hormone decisions be individualized — based on each patient's history, symptom picture, risk factors, bloodwork, and preferences — rather than run through a one-size-fits-all protocol. This is also why published articles like this one cannot responsibly recommend any specific intervention for any individual reader. That's the prescribing clinician's role.

How To Think About the Research From Here

Readers who want to engage with midlife hormone biology seriously have several accessible entry points:

Primary guideline documents. The ISSWSH 2019 Global Consensus Statement, the Endocrine Society's androgen therapy guideline, and NAMS's current hormone therapy position statement are all publicly available and readable. They are dense but are the best sources for "what does the field actually say."

Longitudinal cohort literature. The SWAN study (Study of Women's Health Across the Nation), Women's Health Initiative, and ELITE trial are the large datasets most frequently cited in midlife hormone discussions. Reading the original papers is more informative than reading secondary summaries.

Clinician voices who cite primary literature. A small number of contemporary clinician-communicators consistently reference primary research rather than brand-driven narratives. See our reading list of voices shaping women's biohacking in 2026 for specific names and where to find their work.

A prescribing physician. The practical translation from research to individual clinical decision-making happens in the clinical encounter. No article can do that translation for a reader, and any that claims to is overreaching.

Midlife hormone biology is one of the most active and rapidly evolving areas of women's health research. The published literature supports genuine clinical options that were not available or discussed a decade ago. What is appropriate for any individual patient is a conversation between that patient and a physician trained in this area.

Footnotes

^[1]: Harlow SD, Gass M, Hall JE, et al. "Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging." Journal of Clinical Endocrinology & Metabolism, 2012; 97(4): 1159-1168. ^[2]: Davis SR, Baber R, Panay N, et al. "Global Consensus Position Statement on the Use of Testosterone Therapy for Women." Journal of Clinical Endocrinology & Metabolism, 2019; 104(10): 4660-4666. Endorsed by ISSWSH, IMS, Endocrine Society, and others. ^[3]: Panzer C, Wise S, Fantini G, et al. "Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction." Journal of Sexual Medicine, 2006; 3(1): 104-113.